Glenmark Cleared By U.S. To License Antibody To Sanofi
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Pharmaceuticals and its deal to license its GBR 500 monoclonal antibody to France's Sanofi-Aventis received approval by U.S. antitrust authorities